1
|
Poizeau F, Maruani A, Staumont-Sallé D, Jouan N, Ly S, Schollhammer M, Reverte M, Dibao-Dina C, Duong TA, Matard B, Penso-Assathiany D, Dupuy A, Carriot M, Seï JF, Corgibet F, Guillot B, Barbarot S, Leducq S, Bertolotti A, Tannous J, Chaby G, Jullien D, Pépin E, Quéreux G, Beylot-Barry M, Chosidow O. Promoting clinical research in community-based practice: Threats and opportunities. Ann Dermatol Venereol 2024; 151:103272. [PMID: 38688174 DOI: 10.1016/j.annder.2024.103272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Revised: 12/12/2023] [Accepted: 03/04/2024] [Indexed: 05/02/2024]
Affiliation(s)
- F Poizeau
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail)-UMR_S 1085, F-35000 Rennes, France.
| | - A Maruani
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; CHRU de Tours, Service de Dermatologie, Unité de Dermatologie pédiatrique, 37000 Tours, France; Universités de Tours et de Nantes, Inserm 1246-SPHERE, Nantes, France
| | - D Staumont-Sallé
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; CHU Lille, Service de Dermatologie, Univ Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE) F-59000, Lille, France
| | - N Jouan
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Cabinet de Dermatologie, 29200 Brest, France
| | - S Ly
- Cabinet de Dermatologie, Gradignan, France; Service de Dermatologie, Hôpital St André, Bordeaux, France
| | - M Schollhammer
- Cabinet de Dermatologie, 29200 Brest, France; Service de Dermatologie, CHU Brest, Brest, France
| | - M Reverte
- Cabinet de Dermatologie, 83120 Sainte-Maxime, France
| | - C Dibao-Dina
- Universités de Tours et de Nantes, Inserm 1246-SPHERE, Nantes, France; Département Universitaire de Médecine Générale, Université de Tours, Tours, France
| | - T-A Duong
- Service de dermatologie générale et oncologique, CHU Ambroise Paré, Boulogne-Billancourt, France
| | - B Matard
- Centre Sabouraud, Hôpital Saint Louis, Paris, France
| | | | - A Dupuy
- Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail)-UMR_S 1085, F-35000 Rennes, France
| | - M Carriot
- Infirmière puéricultrice de recherche, CIC 1415 de Tours, Tours, France
| | - J-F Seï
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Fédération Française de Formation Continue et d'Évaluation en Dermatologie Vénéréologie
| | - F Corgibet
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France
| | - B Guillot
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Dermatologue, Université de Montpellier, Montpellier, France
| | - S Barbarot
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Nantes Université, Service de Dermatologie, CHU Nantes, INRAE, UMR 1280, PhAN, F-44000 Nantes, France
| | - S Leducq
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Service de Dermatologie, CHRU Tours, 37000 Tours, France
| | - A Bertolotti
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; CIC-INSERM1410, Service de Maladies Infectieuses - Dermatologie, CHU de la Réunion, Saint Pierre, La Réunion, France
| | - J Tannous
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France
| | - G Chaby
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Service de Dermatologie, CHU Amiens, 80000 Amiens, France
| | - D Jullien
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Hospices Civils de Lyon, Hôpital E. Herriot, Service de Dermatologie, Lyon F-69003; Université Lyon-1, INSERM Unité 1111-CIRI, Lyon F-69007, France
| | - E Pépin
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Dermatologue, FFFCEDV, Villepreux, France
| | - G Quéreux
- Service de Dermatologie, CHU Nantes, Université de Nantes, CIC 1413, Inserm UMR 1302/EMR6001 INCIT, F-44000 Nantes, France
| | - M Beylot-Barry
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Service de Dermatologie, CHU Bordeaux, INSERM U1312, Bordeaux Institute of Oncology, Univ Bordeaux, Bordeaux, France
| | - O Chosidow
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, consultation dermatoses faciales, Paris, France
| |
Collapse
|
2
|
Tran C, Mahé E, Beylot-Barry M, Jullien D, Richard MA, Fougerousse AC, Bouznad A, Bulai Livideanu C, Brun A, Amelot F, Maccari F, Aubin F, Benhadou F, Paul C. Real-life management of psoriasis with biological agents during pregnancy. Ann Dermatol Venereol 2024; 151:103254. [PMID: 38554588 DOI: 10.1016/j.annder.2024.103254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2023] [Accepted: 11/07/2023] [Indexed: 04/01/2024]
Abstract
BACKGROUND French guidelines recommend stopping biologic treatment of psoriasis between 3 and 24 weeks before conception in accordance with the relevant Summary of Product Characteristics (SmPC). The aim of this study was to evaluate the real-life practice of dermatologists in the management of pregnant women with psoriasis previously treated with biologic agents. We wished to assess the level of practitioner adherence to the relevant SmPCs. MATERIAL AND METHODS We conducted a study in collaboration with GRPso and Resopso. A computerized questionnaire was completed by the practitioners. We performed descriptive statistics and studied the profile of the practitioners, their level of confidence with continuation of biological agents during pregnancy, and their reported practices on the use of biological agents in pregnancy. Statistical analyses were performed using XLSTAT. A p-value of less than 0.05 was considered significant. RESULTS A total of 63 dermatologists (women: 71%; mean age 43.8 years) participated in this study, the majority of whom were hospital-based (87%). Recommendations were followed by 36.5% of practitioners, while 44% reported discontinuing biologic agents on diagnosis of pregnancy, and 20.5% reported using these agents during pregnancy. Among dermatologists with more than ten years of experience, 19% reported following the SmPC. Among dermatologists with a patient base >200 (patients treated with biologic agents for psoriasis), 19% reported following the SmPC compared to 54% of practitioners with less than 50 patients. The mean age of dermatologists following the SmPC was 41 years vs. 47 years for those not following the SmPC. DISCUSSION The majority of practitioners do not follow recommendations on discontinuation of biologic agents before the planning of pregnancy by patients.
Collapse
Affiliation(s)
- C Tran
- Department of Dermatology, Toulouse University Hospital, 31400 Toulouse, France
| | - E Mahé
- Department of Dermatology, Victor Dupouy Hospital, 95107 Argenteuil, France; Groupe d'Etudes Multicentriques (GEM) Resopso, France; GRPso (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), France
| | - M Beylot-Barry
- Department of Dermatology, Bordeaux University Hospital, 33000 Bordeaux, France; GRPso (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), France
| | - D Jullien
- Department of Dermatology, Lyon University Hospital, 69003 Lyon, France; GRPso (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), France
| | - M-A Richard
- Department of Dermatology, Marseille University Hospital, 13005 Marseille, France; GRPso (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), France
| | - A-C Fougerousse
- Department of Dermatology, Hôpital d'Instruction des Armées Bégin, France; Groupe d'Etudes Multicentriques (GEM) Resopso, France
| | - A Bouznad
- Department of Dermatology, Toulouse University Hospital, 31400 Toulouse, France
| | - C Bulai Livideanu
- Department of Dermatology, Toulouse University Hospital, 31400 Toulouse, France; Groupe d'Etudes Multicentriques (GEM) Resopso, France
| | - A Brun
- Department of Dermatology, Toulouse University Hospital, 31400 Toulouse, France
| | - F Amelot
- Department of Dermatology, Carcassonne Hospital, 11000 Carcassonne, France
| | - F Maccari
- Department of Dermatology, Hôpital d'Instruction des Armées Bégin, France; Groupe d'Etudes Multicentriques (GEM) Resopso, France
| | - F Aubin
- Department of Dermatology, Besançon University Hospital, 25000 Besançon, France; GRPso (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), France
| | - F Benhadou
- Department of Dermatology, Erasme Hôpital universitaire, Université Libre de Bruxelles, 1070 Brussels, Belgium; Groupe d'Etudes Multicentriques (GEM) Resopso, France
| | - C Paul
- Department of Dermatology, Toulouse University Hospital, 31400 Toulouse, France; GRPso (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), France.
| |
Collapse
|
3
|
Marcé D, Canu D, Laurent C, Pottier C, Jullie ML, Kervarrec T, Beylot-Barry M, Samimi M. Subcutaneous panniculitis-like T-cell lymphoma presenting as facial infiltration with long-term response to methotrexate: Two cases. Ann Dermatol Venereol 2023; 150:294-296. [PMID: 37442745 DOI: 10.1016/j.annder.2023.04.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2022] [Revised: 12/30/2022] [Accepted: 04/11/2023] [Indexed: 07/15/2023]
Affiliation(s)
- D Marcé
- Dermatology Department, University Hospital of Tours, 37000 Tours, France
| | - D Canu
- Dermatology Department, University Hospital of Bordeaux, 33000 Bordeaux, France
| | - C Laurent
- Dermatology Department, University Hospital of Rennes, 35000 Rennes, France
| | - C Pottier
- Dermatology Department, University Hospital of Tours, 37000 Tours, France
| | - M-L Jullie
- Pathology Department, University Hospital of Bordeaux, 33000 Bordeaux, France
| | - T Kervarrec
- Pathology Department, University Hospital of Tours, 37000 Tours, France
| | - M Beylot-Barry
- Dermatology Department, University Hospital of Bordeaux, 33000 Bordeaux, France; Univ. Bordeaux, UMR 1312 INSERM, 33000 Bordeaux, France
| | - M Samimi
- Dermatology Department, University Hospital of Tours, 37000 Tours, France.
| |
Collapse
|
4
|
Breton N, Bruneau L, Dumez J, Miquel J, Villeroy F, Beylot-Barry M, Sultan-Bichat N, Bertolotti A. Evaluation of parents' knowledge following a sun-protection campaign in schools in La Reunion. Ann Dermatol Venereol 2023; 150:287-289. [PMID: 37821252 DOI: 10.1016/j.annder.2023.03.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2022] [Revised: 01/05/2023] [Accepted: 03/31/2023] [Indexed: 10/13/2023]
Affiliation(s)
- N Breton
- Mission Soleil Réunion, Saint Paul, La Réunion, France
| | - L Bruneau
- CHU Réunion, Unité de Soutien Méthodologique, Saint Denis, La Réunion, France; Inserm CIC1410, CHU Réunion, Saint Pierre, La Réunion, France
| | - J Dumez
- Inserm CIC1410, CHU Réunion, Saint Pierre, La Réunion, France; Département de Médecine Générale, Université de La Réunion, La Réunion, France.
| | - J Miquel
- Mission Soleil Réunion, Saint Paul, La Réunion, France; CHU Réunion, Unité de Dermatologie - pédiatrique, Saint Pierre, La Réunion, France
| | - F Villeroy
- Mission Soleil Réunion, Saint Paul, La Réunion, France; CHU Réunion, Service d'Ophtalmologie, Saint Denis, La Réunion, France
| | | | - N Sultan-Bichat
- Mission Soleil Réunion, Saint Paul, La Réunion, France; CH Ouest Réunion, Service de Dermatologie, Saint Paul, La Réunion, France
| | - A Bertolotti
- Mission Soleil Réunion, Saint Paul, La Réunion, France; Inserm CIC1410, CHU Réunion, Saint Pierre, La Réunion, France; CHU Réunion, Service des Maladies Infectieuses - Dermatologie, Saint Pierre, La Réunion, France
| |
Collapse
|
5
|
Beylot-Barry M, Quereux G, Nardin C, Duval-Modeste AB, Dereure O, Dalac-Rat S, Dobos G, Pham-Ledard A, Ram-Wolff C, D'Incan M, Grange F, Braniste V, Bagot M. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study. J Eur Acad Dermatol Venereol 2023; 37:1777-1784. [PMID: 37113040 DOI: 10.1111/jdv.19134] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2022] [Accepted: 03/29/2023] [Indexed: 04/29/2023]
Abstract
BACKGROUND Efficacy and safety of mogamulizumab, a monoclonal antibody directed against C-C chemokine receptor 4, were demonstrated in a previous multinational clinical trial conducted in patients with previously treated cutaneous T-cell lymphoma (CTCL): Sézary syndrome (SS) or Mycosis Fungoides (MF). OBJECTIVES The real-world French OMEGA study aimed to describe effectiveness and tolerability of mogamulizumab in adult patients with CTCL, overall and according to the disease (SS or MF). METHODS In this retrospective study, patients treated with mogamulizumab for SS or MF were included from 14 French expert centres. The overall response rate (ORR) under treatment was described (primary criterion), as well as treatment use and safety data. RESULTS The 122 analysed patients (69 SS, 53 MF) were aged 66.6 ± 12.1 years at mogamulizumab initiation, and their median disease duration was 2.5 years (IQR: 1.3-5.6). Prior to treatment start, they received a median of three systemic CTCL therapies (2-5). Overall, 77.8% of patients suffered from advanced disease (Stage IIB-IVB), with frequent blood (B1/B2) involvement (67.5%). Over the treatment period (median: 4.6 months, 2.1-7.2), 96.7% of patients received all the planned mogamulizumab infusions. Among the 109 patients evaluable for effectiveness, ORR was 58.7% (95% CI [48.9-68.1]) overall, 69.5% [56.1-80.8] in SS and 46.0% [31.8-60.7] in MF. Compartmental response in the blood was observed in 81.8% [69.1-90.9] of SS patients. Skin responses were observed in 57.0% [47.0-66.5] of patients overall, 66.7% [52.9-78.6] in SS and 46.0% [31.8-60.7] in MF. The most common serious adverse drug reactions were rash (8.1% of patients) and infusion-related reactions (2.4%) which led to treatment discontinuation in 7.3% and 0.8% of patients, respectively. One patient with SS died from mogamulizumab-related tumour lysis syndrome. CONCLUSIONS This large French study confirmed the effectiveness and tolerability of mogamulizumab in SS and MF patients in routine medical practice.
Collapse
Affiliation(s)
- M Beylot-Barry
- BoRdeaux Institute of Oncology, INSERM U1312, Team 5, Bordeaux University, Bordeaux, France
- Dermatology Department, CHU Bordeaux, Bordeaux, France
| | - G Quereux
- Dermatology Department, Nantes University Hospital, University of Nantes, CIC 1413, INSERM UMR 1302/EMR6001 INCIT, Nantes, France
| | - C Nardin
- Dermatology Department, Minjoz Hospital, CHU Besancon, Besancon, France
- INSERM U1098, University of Franche Comté, EFS Bourgogne Franche-Comté and Franche-Comté University, Besançon, France
| | - A-B Duval-Modeste
- Department of Dermatology, INSERM U519, Rouen University Hospital, Rouen, France
| | - O Dereure
- Department of Dermatology, University of Montpellier, Montpellier, France
| | - S Dalac-Rat
- Dermatology Department, Dijon Bourgogne University Hospital, Dijon, France
| | - G Dobos
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France
- INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France
- Université Paris Cité, Paris, France
- Department of Dermatology, HTCC, Charité-Universitaetsmedizin Berlin, Berlin, Germany
| | - A Pham-Ledard
- BoRdeaux Institute of Oncology, INSERM U1312, Team 5, Bordeaux University, Bordeaux, France
- Dermatology Department, CHU Bordeaux, Bordeaux, France
| | - C Ram-Wolff
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France
| | - M D'Incan
- Dermatology and Cutaneous Oncology, Estaing University Hospital, University of Clermont-Ferrand, Clermont-Ferrand, France
| | - F Grange
- Department of Dermatology, Valence Hospital, Valence, France
| | - V Braniste
- Kyowa Kirin Pharma, Medical Affairs, Neuilly-sur-Seine, France
| | - M Bagot
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France
- INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France
- Université Paris Cité, Paris, France
| |
Collapse
|
6
|
Toulemonde E, Chevret S, Battistella M, Neidhardt EM, Nardin C, Le Du F, Meyer N, Véron M, Gambotti L, Lamrani-Ghaouti A, Jamme P, Chaffaut C, De Pontville M, Saada-Bouzid E, Beylot-Barry M, Simon C, Jouary T, Marabelle A, Mortier L. Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas. Cancer Immunol Immunother 2023:10.1007/s00262-023-03449-9. [PMID: 37067554 DOI: 10.1007/s00262-023-03449-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2022] [Accepted: 04/06/2023] [Indexed: 04/18/2023]
Abstract
Trichoblastic carcinoma is a rare malignant cutaneous adnexal tumor with a risk of local invasion and distant metastasis. As of today, there is no consensus for the treatment of locally advanced or metastatic trichoblastic carcinoma. "AcSé Nivolumab" is a multi-center Phase II basket clinical trial (NCT03012581) evaluating the safety and efficacy of nivolumab in several cohorts of rare, advanced cancers. Here we report the results of nivolumab in patients with trichoblastic carcinoma. Of the eleven patients enrolled in the study, five patients had been previously treated by sonic hedgehog inhibitors. The primary endpoint 12-week objective response rate was 9.1% (N = 1/11) with 1 partial response. Six patients who progressed under previous lines of treatment showed stable disease at 12 weeks, reflecting a good control of the disease with nivolumab. Furthermore, 54.5% of the patients (N = 6/11) had their disease under control at 6 months. The 1-year overall survival was 80%, and the median progression-free survival was 8.4 months (95%CI, 5.7 to NA). With 2 responders (2 complete responses), the best response rate to nivolumab at any time was 18.2% (95%CI, 2.3-51.8%). No new safety signals were identified, and adverse events observed herein were previously described and well known with nivolumab monotherapy. These results are promising, suggesting that nivolumab might be an option for patients with advanced trichoblastic carcinomas. Further studies on larger cohorts are necessary to confirm these results and define the role of nivolumab in the treatment of trichoblastic carcinomas.
Collapse
Affiliation(s)
- E Toulemonde
- Department of Dermatology, Claude Huriez Hospital, CHU de Lille, Lille, France.
| | - S Chevret
- Department of Biostatistics, Saint Louis Hospital, AP-HP, Paris, France
| | - M Battistella
- Department of Pathology, Saint Louis Hospital, AP-HP, Université Paris Cité, INSERM U976, Paris, France
- CARADERM Network, Lille, France
| | - E M Neidhardt
- Department of Oncology, Centre Léon Berard, Lyon, France
| | - C Nardin
- Department of Dermatology, CHU Besançon and INSERM 1098, Besançon, France
| | - F Le Du
- Department of Oncology, CLCC Eugène Marquis, Rennes, France
| | - N Meyer
- Department of Oncodermatology, IUC and CHU Toulouse, Toulouse, France
| | - M Véron
- Department of Dermatology, Claude Huriez Hospital, CHU de Lille, Lille, France
| | - L Gambotti
- Department of Clinical Research, Institut National Contre Le Cancer (INCa), Paris, France
| | | | - P Jamme
- Department of Dermatology, Claude Huriez Hospital, CHU de Lille, Lille, France
| | - C Chaffaut
- Department of Biostatistics, Saint Louis Hospital, AP-HP, Paris, France
| | - M De Pontville
- Department of Dermatology, CHU Caen, Caen, France
- CARADERM Network, Lille, France
| | - E Saada-Bouzid
- Department of Medical Oncology, Centre Antoine Lacassagne, Côte d'Azur University, Nice, France
| | - M Beylot-Barry
- Department of Dermatology, CHU Bordeaux, INSERM U1312, Bordeaux, France
- CARADERM Network, Lille, France
| | - C Simon
- Département R&D Unicancer, Paris, France
| | - T Jouary
- Department of Dermatology, François Mitterrand Hospital, Pau, France
- CARADERM Network, Lille, France
| | - A Marabelle
- Department of Therapeutic Innovations and Early Clinical Trials, INSERM U1015 & CIC1428, University of Paris Saclay, Gustave Roussy, Villejuif, France
| | - L Mortier
- Department of Dermatology, Claude Huriez Hospital, CARADERM and University of Lille, U1189 Inserm, 59000, Lille, France
- CARADERM Network, Lille, France
| |
Collapse
|
7
|
Arlegui H, Mahé E, Richard MA, De Rycke Y, Viguier M, Beylot-Barry M, Dupuy A, Beneton N, Joly P, Jullien D, Bachelez H, Sbidian É, Chosidow O, Paul C, Tubach F. Impact of the first wave of the COVID-19 pandemic on the treatment of psoriasis with systemic therapies in France: Results from the PSOBIOTEQ cohort. Ann Dermatol Venereol 2023:S0151-9638(23)00009-1. [PMID: 36914553 PMCID: PMC9928748 DOI: 10.1016/j.annder.2023.01.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Revised: 11/18/2022] [Accepted: 01/31/2023] [Indexed: 02/17/2023]
Abstract
BACKGROUND The nature of the COVID-19 pandemic led to concerns among patients and physicians about the potential impact of immunosuppressive treatments for chronic diseases such as psoriasis on the risk of severe COVID-19. OBJECTIVES To describe treatment modifications and determine the incidence of COVID-19 infection among psoriasis patients during the first wave of the pandemic, and identify the factors associated with these events. METHODS Data from PSOBIOTEQ cohort relating to the first COVID-19 wave in France (March to June, 2020), as well as a patient-centred COVID-19 questionnaire, were used to evaluate the impact of lockdown on changes (discontinuations, delays or reductions) in systemic therapies, and to determine the incidence of COVID-19 cases among these patients. Logistic regression models were used to assess associated factors. RESULTS Among the 1751 respondents (89.3%), 282 patients (16.9%) changed their systemic treatment for psoriasis, with 46.0% of these changes being initiated by the patients themselves. Patients were more likely to experience psoriasis flare-ups during the first wave if they changed their treatment during this period (58.7% vs 14.4%; P < 0.0001). Changes to systemic therapies were less frequent among patients with cardiovascular diseases (P < 0.001), and those aged ≥ 65 years (P = 0.02). Overall, 45 patients (2.9%) reported having COVID-19, and eight (17.8%) required hospitalization. Risk factors for COVID-19 infection were close contact with a positive case (P < 0.001) and living in a region with a high incidence of COVID-19 (P < 0.001). Factors associated with a lower risk of COVID-19 were avoiding seeing a physician (P = 0.002), systematically wearing a mask during outings (P = 0.011) and being a current smoker (P = 0.046). CONCLUSIONS Discontinuation of systemic psoriasis treatments during the first COVID-19 wave (16.9%) - mainly decided by patients themselves (46.0%) - was associated with a higher incidence of disease flares (58.7% vs 14.4%). This observation and factors associated with a higher risk of COVID-19 highlight the need to maintain and adapt patient-physician communication during health crises according to patient profiles, with the aim of avoiding unnecessary treatment discontinuations and ensuring that patients are informed about the risk of infection and the importance of complying with hygiene rules.
Collapse
Affiliation(s)
- H Arlegui
- AP-HP, Hôpital Pitié-Salpêtrière, Centre de Pharmaco-épidémiologie (Cephépi), INSERM, CIC-1901, Paris, France
| | - E Mahé
- Service de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France
| | - M-A Richard
- Service de Dermatologie, EA 3279: CEReSS - Health Service Research and Quality of Life Centre, Timone Hospital, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University, Marseille, France
| | - Y De Rycke
- Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Pharmaco-épidémiologie (Cephépi), CIC-1901, 75013 Paris, France
| | - M Viguier
- Service de Dermatologie-Vénéréologie, Hôpital Robert Debré, Université Reims Champagne Ardenne, 51100 Reims, France
| | - M Beylot-Barry
- Service de Dermatologie, CHU de Bordeaux, Translational Research on Oncodermatology and Rare skin diseases, Bordeaux Institute of Oncology, UMR 1312 INSERM, Université Bordeaux, Bordeaux, France
| | - A Dupuy
- France Univ Rennes, CHU Rennes, 35000 Rennes, France
| | - N Beneton
- REPERES Pharmaco-Epidemiology and Health Services Research, University Rennes and French School of Public Health, Rennes, France
| | - P Joly
- Service de Dermatologie, Hôpital du Mans, Le Mans, France
| | - D Jullien
- Service de Dermatologie, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon F-69003; Lyon-1 University; INSERM U1111 - CIRI, Lyon F-69007, France
| | - H Bachelez
- Service de Dermatologie, Assistance Publique- Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris Cité, Paris, France; INSERM UMR1163, Institut Imagine, Paris, France
| | - É Sbidian
- Service de Dermatologie, Assistance Publique- Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris Cité, Paris, France; Hôpital Henri Mondor, Clinical Investigation Centre, Université Paris-Est Créteil (UPEC), Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) - EA 7379, Créteil, France
| | - O Chosidow
- Service de Dermatologie, Assistance Publique- Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris Cité, Paris, France; Groupe de recherche Dynamyc, EA7380, Faculté de Santé de Créteil, École nationale vétérinaire d'Alfort, USC ANSES, Université Paris-Est Créteil, Créteil, France
| | - C Paul
- Service de Dermatologie, Toulouse University Hospital (CHU), Paul Sabatier University, Toulouse, France
| | - F Tubach
- Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Pharmaco-épidémiologie (Cephépi), CIC-1901, 75013 Paris, France.
| | | |
Collapse
|
8
|
Petiot A, Heron-Mermin D, Leyral C, Seneschal J, Beylot-Barry M. The harmful effects of aesthetic care: Dealing with new kinds of exogenous acne. Ann Dermatol Venereol 2022; 149:289-290. [PMID: 35688669 DOI: 10.1016/j.annder.2022.02.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2021] [Revised: 11/22/2021] [Accepted: 02/09/2022] [Indexed: 12/30/2022]
Affiliation(s)
- A Petiot
- Department of Dermatology, Saint-André Hospital, Bordeaux University Hospital, 33000 Bordeaux, France
| | - D Heron-Mermin
- Department of Dermatology, Saint-André Hospital, Bordeaux University Hospital, 33000 Bordeaux, France
| | - C Leyral
- Private dermatology practice, 33127 Martignas-sur-Jalle, France
| | - J Seneschal
- Department of Dermatology, Saint-André Hospital, Bordeaux University Hospital, 33000 Bordeaux, France
| | - M Beylot-Barry
- Department of Dermatology, Saint-André Hospital, Bordeaux University Hospital, 33000 Bordeaux, France.
| |
Collapse
|
9
|
Dousset L, Michon P, Mahfouf W, Muzotte E, Guzzo G, Beylot-Barry M, Rezvani H. 480 Inhibition of DHODH reduces efficiently tumor growth in a subgroup of cutaneous squamous cell carcinoma with a particular metabolic profile. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
10
|
Zagala R, Amico S, Laban E, Fontès-Plantade V, Beylot-Barry M, Pham-Ledard A. Primary intralymphatic histiocytosis: Case report and literature review. Ann Dermatol Venereol 2022; 149:298-305. [PMID: 35817611 DOI: 10.1016/j.annder.2022.05.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2021] [Revised: 02/15/2022] [Accepted: 05/24/2022] [Indexed: 12/31/2022]
Affiliation(s)
- R Zagala
- Dermatology department, CHU Bordeaux, 33000 Bordeaux, France.
| | - S Amico
- Dermatology department, CHU Bordeaux, 33000 Bordeaux, France
| | - E Laban
- Pathology practice, 33400 Talence, France
| | | | - M Beylot-Barry
- Dermatology department, CHU Bordeaux, 33000 Bordeaux, France; University Medical Research Unit (UMR) 1312, Bordeaux Institute of Oncology, Team 5 Translational Research on Oncodermatology and Orphean skin diseases, University of Bordeaux, 33000 Bordeaux, France
| | - A Pham-Ledard
- Dermatology department, CHU Bordeaux, 33000 Bordeaux, France; University Medical Research Unit (UMR) 1312, Bordeaux Institute of Oncology, Team 5 Translational Research on Oncodermatology and Orphean skin diseases, University of Bordeaux, 33000 Bordeaux, France
| |
Collapse
|
11
|
Maruani A, Barbarot S, Gangneux JP, Caseris M, Moreau C, Brun S, Botterel F, Menotti J, Toubiana J, Chouchana L, Beylot-Barry M, Dupin N, Guillot B, Chosidow O. Management of tinea capitis in children following the withdrawal of griseofulvin from the French market: A fast-track algorithm proposed by the Center of Evidence of the French Society of Dermatology. Ann Dermatol Venereol 2022; 149:238-240. [PMID: 36229261 DOI: 10.1016/j.annder.2022.07.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Revised: 01/07/2022] [Accepted: 07/12/2022] [Indexed: 11/06/2022]
Affiliation(s)
- A Maruani
- Universités de Tours et Nantes, Inserm 1246-SPHERE, CHRU de Tours, service de dermatologie, unité de dermatologie pédiatrique, 37000 Tours, France; Centre de Preuves en Dermatologie, Société Française de Dermatologie Pédiatrique, Société Française de Dermatologie, France.
| | - S Barbarot
- Centre de Preuves en Dermatologie, Société Française de Dermatologie Pédiatrique, Société Française de Dermatologie, France; Nantes Université, Servie de Dermatologie, CHU Nantes, UMR 1280 PhAN, INRAE, F-44000 Nantes, France
| | - J P Gangneux
- Service de Parasitologie-Mycologie, CHU de Rennes, Univ Rennes, Inserm, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F35000 Rennes, France; Société Française de Mycologie Médicale, France
| | - M Caseris
- Infectiologie mobile, Hôpital Robert Debré, AP-HP, 75019 Paris, France; Groupe de Pathologie Infectieuse Pédiatrique de la Société Française de Pédiatrie, France
| | - C Moreau
- Service Pharmacie, Hôpital Robert-Debré (AP-HP), 75019 Paris, France
| | - S Brun
- Service de Parasitologie-Mycologie, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, France; Société Française de Mycologie Médicale, France
| | - F Botterel
- Unité de Parasitologie - Mycologie, Département de Prévention, diagnostic et traitement des infections, CHU de Créteil, AP-HP, Université Paris Est Créteil, Créteil, France; Société Française de Mycologie Médicale, France
| | - J Menotti
- Service de Parasitologie et Mycologie Médicale, Institut des Agents Infectieux, Hospices Civils de Lyon / Université Lyon 1, Lyon, France; Société Française de Mycologie Médicale, France
| | - J Toubiana
- Service de pédiatrie générale et maladies infectieuses, Hôpital Necker Enfants malades, AP-HP, Université de Paris, Paris, France
| | - L Chouchana
- Centre Régional de Pharmacovigilance, Service de Pharmacologie, EA 7323 Pharmacologie et Evaluation des Thérapeutiques chez l'enfant et la femme enceinte, Hôpital Cochin, AP-HP, Université de Paris, Paris, France; Société Française de Pharmacologie et Thérapeutique, France
| | - M Beylot-Barry
- Service de Dermatologie, CHU de Bordeaux, INSERM U1312, Bordeaux, France; Centre de Preuves en Dermatologie, Société Française de Dermatologie, France
| | - N Dupin
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, France; Service de dermatologie Hôpital Cochin AP-HP, Paris, France
| | - B Guillot
- Université de Montpellier, Montpellier, France
| | - O Chosidow
- Service de Dermatologie, Hôpitaux Universitaires Henri-Mondor, AP-HP, Créteil, France; Universités de Tours et Nantes, Inserm 1246-SPHERE, France; Centre de Preuves en Dermatologie, GrIDIST Groupe Infectiologie Dermatologique, ISD-SIDA, Société Française de Dermatologie, Paris, France
| |
Collapse
|
12
|
Najidh S, Van der Sluijs Gelling AJ, Cozzio A, Dobos G, Bagot M, Beylot-Barry M, Guenova E, Nicolay J, Lima M, Ortiz-Romero PL, Papadavid E, Pujol R, Quaglino P, Stadler R, Wehkamp U, Whittaker S, Van Dongen JJM, Montero JF, Almeida J, Vermeer MH. Immunophenotypic identification and characterization of CTCL tumor cells in blood using standardized flow cytometry: a European multicenter study. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00548-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
13
|
Gros A, Gerber Z, Menguy S, Ducharme O, Bresson-Bepoldin L, Vergier B, Beylot-Barry M, Pham-Ledard A, Merlio JP. Transcriptomic landscape of primary cutaneous diffuse large B-cell lymphoma, leg type reveals novel therapeutic clues. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00567-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
14
|
Mitsunaga K, Bagot M, Beylot-Barry M, Ram-Wolff C, Guenova E, Fassnacht C, Hodak E, Amitay I, Papadavid E, Jonak C, Porkert S, Scarisbrick J, Applewaite R, Nicolay J, Quaglino P, Sanches Jr J, Martins JC, Ortiz-Romero PL. Real-world study of the use of pegylated interferon alfa for treatment of primary cutaneous T-cell lymphomas: an EORTC CLTF study. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00599-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
15
|
Pham-Ledard A, Menguy S, Prochazkova-Carlotti M, Azzi-Martin L, Ferte T, Bresson-Bepoldin L, Vergier B, Merlio JP, Beylot-Barry M. Proliferative tumor infiltrating lymphocytes within microenvironment impact prognosis in cutaneous B-cell lymphomas. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00560-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
16
|
Bagot M, Muller M, Kim YH, Ortiz-Romero PL, Zinzani PL, Beylot-Barry M, Dalle S, Jacobsen E, Combalia A, Huen A, Mehta-Shah N, Khodadoust MS, Viotti J, Paiva C, Porcu P. Lacutamab in patients with advanced mycosis fungoides according to KIR3DL2 expression: stage 1 results from the TELLOMAK phase 2 trial. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00590-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Cottron C, Treton X, Altwegg R, Reenaers C, Amiot A, Fumery M, Vuitton L, Peyrin-Biroulet L, Bouguen G, Dewit O, Nancey S, Caillo L, Roblin X, Beylot-Barry M, Rivière P, Laharie D. How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study. J Crohns Colitis 2022; 16:1202-1210. [PMID: 35218189 DOI: 10.1093/ecco-jcc/jjac035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Revised: 02/01/2022] [Accepted: 02/24/2022] [Indexed: 02/08/2023]
Abstract
BACKGROUND AND AIMS Optimal management of patients with inflammatory bowel disease [IBD] after anti-tumour necrosis factor [TNF] discontinuation due to severe induced skin lesions is unclear. Our study aimed to describe dermatological and IBD evolution after anti-TNF discontinuation for this side effect. METHODS We conducted a multicentre retrospective study including consecutive IBD patients who discontinued anti-TNF due to severe induced skin lesions. Our objectives were to determine factors associated with dermatological remission [complete disappearance of skin lesions] and with IBD relapse in patients with inactive disease at inclusion, notably the impact of an early switch to another biological agent within 3 months of anti-TNF discontinuation. RESULTS Among the 181 patients [134 women, 160 Crohn's disease] included in the 13 participating centres, dermatological remission occurred in 110 [62%] patients with a median [interquartile range, IQR] interval of 8.0 [6.8-11.0] months. Scalp location was independently associated with less remission of skin lesions (hazard ratio [HR] = 0.64 [95% CI 0.43-0.94], p = 0.02) while early switch was independently associated with a higher probability of remission of skin lesions (HR = 1.64 [95% CI 1.1-2.5], p = 0.02). Among the 148 patients with inactive IBD at inclusion, disease relapse occurred in 75 [51%] patients with a median [IQR] interval of 26.0 [23.0-39.1] months. Survival rates without IBD relapse at 1 year were 85.8% [95% CI 77.5-94.9] in the early switch group and 59.3% [95% CI 48.9-71.9] in the other group [p < 0.01]. CONCLUSIONS Early switch to a new biological is associated with a higher probability of healing of anti-TNF-induced skin lesions and significantly reduces the risk of IBD relapse.
Collapse
Affiliation(s)
- C Cottron
- CHU de Bordeaux, Hôpital Haut-Lévêque, Service d'Hépato-gastroentérologie et oncologie digestive - Université de Bordeaux, F-33000 Bordeaux, France
| | - X Treton
- Department of Gastroenterology, IBD and Nutrition, Beaujon Hospital, APHP, Paris, France
| | - R Altwegg
- Department of Hepatogastroenterology, Saint Eloi Hospital, CHU de Montpellier, Montpellier, France
| | - C Reenaers
- Department of Gastroenterology, CHU Sart Tilman, Liège, Belgium
| | - A Amiot
- Department of Gastroenterology, Henri Mondor Hospital, APHP, Creteil, France
| | - M Fumery
- Department of Gastroenterology, CHU de Amiens, and Peritox, UMR I-01, France
| | - L Vuitton
- Department of Hepatogastroenterology, CHRU de Besançon, Besançon, France
| | - L Peyrin-Biroulet
- Department of Hepatogastroenterology, Nancy University Hospital, Vandoeuvre les Nancy, France
| | - G Bouguen
- CHU Rennes, Univ Rennes, INSERM, CIC1414, Institut NUMECAN (Nutrition Metabolism and Cancer), F-35000 Rennes, France
| | - O Dewit
- Department of Gastroenterology, Université Catholique de Louvain Saint Luc, Brussels, Belgium
| | - S Nancey
- Department of Gastroenterology, CHU de Lyon, Lyon Sud Hospital, University Claude Bernard Lyon 1, INSERM U1111, Lyon, France
| | - L Caillo
- Department of Hepatogastroenterology, CHU de Nîmes, Nîmes, France
| | - X Roblin
- Department of Hepatogastroenterology, CHU de Saint-Etienne, Hôpital Nord, Université Jean Monnet, Saint-Etienne, France
| | - M Beylot-Barry
- Department of Dermatology, Saint-André Hospital, CHU de Bordeaux, France
| | - P Rivière
- CHU de Bordeaux, Hôpital Haut-Lévêque, Service d'Hépato-gastroentérologie et oncologie digestive - Université de Bordeaux, F-33000 Bordeaux, France
| | - D Laharie
- CHU de Bordeaux, Hôpital Haut-Lévêque, Service d'Hépato-gastroentérologie et oncologie digestive - Université de Bordeaux, F-33000 Bordeaux, France
| |
Collapse
|
18
|
Canu D, Pham-Ledard A, Ouhabrache N, Beylot-Barry M. Changes in total skin electron beam therapy modalities for mycosis fungoides: A single-centre study. Ann Dermatol Venereol 2022; 149:180-184. [PMID: 35595588 DOI: 10.1016/j.annder.2022.02.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2021] [Revised: 10/20/2021] [Accepted: 02/16/2022] [Indexed: 11/25/2022]
Abstract
BACKGROUND Mycosis fungoides (MF) is a highly radiosensitive disease. Total skin electron beam therapy (TSEBT) is an effective option that may allow prolonged response for several months. Recently, a low-dose regimen (12 Gy) has been reported more frequently, with less complete response than for standard doses (36 Gy) but better safety. Our aim was to compare patients treated with 12-Gy and 36-40-Gy TSEBT regimens at our centre for efficacy and safety. METHODS This retrospective, monocentric study in Bordeaux University Hospital included all MF patients treated with 12-Gy or 36-40-Gy TSEBT between 2011 and 2020. RESULTS Patients presented with MF at the following stages: 15 T2, including 9 folliculotropic MF; 2 T3, including 1 folliculotropic; 8 T4, including 2 Sézary syndromes. The mean follow-up time after TSEBT was 43.5 months [range: 2-128] for the 36-40-Gy group and 25.2 months [range: 4-45] for the 12-Gy group. The 3-month overall response rate (ORR) was similar for both groups (84.6% for 36-40 Gy and 91.7% for 12 Gy), but there was a tendency to more complete response in the 36-40-Gy group (30.8% vs 8.3%, P=0.35). Progression-free survival (PFS) tended to be better in the 36-40-Gy group than in the low-dose group (15.7 months vs 5.3 months; P=0.28). Patients treated with low-dose TSEBT had a lower incidence of radiation dermatitis (16.7% vs 38.4%, P=0.42). CONCLUSION We confirm that TSEBT is an effective option, including at lower doses. Differences between low- and standard-dose regimens were not significant in our series. Although a low-dose regimen seemed to result in lower complete response and long-term efficacy rates in comparison with a standard dose, treatment at lower doses presents the advantage of repeatability, with fewer and weaker side effects, in the event of disease recurrence. Second-line treatments were mostly skin-directed in this group.
Collapse
Affiliation(s)
- D Canu
- Department of Dermatology, Hôpital Saint-André, CHU de Bordeaux, 33000 Bordeaux, France
| | - A Pham-Ledard
- Department of Dermatology, Hôpital Saint-André, CHU de Bordeaux, 33000 Bordeaux, France; Inserm, U 1312, Translational Research on Oncodermatology and Orphean skin diseases, BRIC, University of Bordeaux, RIC - UMR, 33000 Bordeaux, France
| | - N Ouhabrache
- Department of Radiotherapy, Hôpital Haut-Lévêque, CHU de Bordeaux, 33600 Pessac, France
| | - M Beylot-Barry
- Department of Dermatology, Hôpital Saint-André, CHU de Bordeaux, 33000 Bordeaux, France; Inserm, U 1312, Translational Research on Oncodermatology and Orphean skin diseases, BRIC, University of Bordeaux, RIC - UMR, 33000 Bordeaux, France.
| |
Collapse
|
19
|
Curmin R, Guillo S, De Rycke Y, Bachelez H, Beylot-Barry M, Beneton N, Olivier C, Dupuy A, Joly P, Jullien D, Richard M, Viguier M, Sbidian E, Paul C, Mahé E, Tubach F. Switchs de biothérapies chez les patients atteints de psoriasis modéré à sévère dans la cohorte française PSOBIOTEQ. Rev Epidemiol Sante Publique 2022. [DOI: 10.1016/j.respe.2022.03.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
20
|
Amici JM, Bergqvist C, Ly S, Corgibet F, Seï JF, Seneschal J, Sbidian E, Beylot-Barry M. CITY-PSO: Prescribing behaviour of French private-practice dermatologists in psoriasis management: An observational, multicentre, cross-sectional study. Ann Dermatol Venereol 2022; 149:169-175. [PMID: 35181154 DOI: 10.1016/j.annder.2022.01.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2021] [Revised: 10/24/2021] [Accepted: 01/04/2022] [Indexed: 12/01/2022]
Abstract
BACKGROUND Information regarding the prescribing behaviour of French private-practice dermatologists (PPDs) is scarce. OBJECTIVES First, to describe the population of PPDs involved in psoriasis management. Second, to describe the population of adult patients treated for psoriasis and their management. METHODS We published a call for participation targeting PPDs; we first asked respondents to complete a form regarding their prescribing behaviour, and then to include consecutive patients consulting for psoriasis during a one-month study period and to collect patient data. RESULTS The 94 participating PPDs included 1022 patients of mean age 52.9±17.9 years. The average body mass index was 28, and 25% had vascular comorbidities. Two thirds of patients had chronic psoriasis, for which 45% had consulted at least 5 times. Psoriasis was mostly with plaques (70.8%) and 11.4% of patients had psoriatic arthritis. The average body surface area (BSA) affected was 10.1%. Among the 679 patients without initial systemic treatment, 159 were started on systemic treatment. The main agents initiated were phototherapy (n=63), methotrexate (n=40), acitretin (n=30) and apremilast (n=20). In multivariate analysis, a higher BSA [Odds Ratio (OR) 1.10, 95% Confidence Interval (CI): 1.07-1.13; P<10-4] and Dermatology Life Quality Index (DLQI) [OR 1.09, 95% CI: 1.03-1.15; P=0.04] were associated with prescription of systemic therapy at the end of the consultation. CONCLUSION The main limitation of our study was that participating PPDs were strongly involved in psoriasis management, which accounts for the high proportion of moderate-to-severe psoriasis and prescription of systemic treatments. Such committed PPDs and the development of psoriasis networks are key factors for improving the quality of care provided to psoriasis patients.
Collapse
Affiliation(s)
- J-M Amici
- Association des Dermato-Vénéréologues du Sud-Ouest (ADVSO, Association of Dermatologists and Venerologists of the French South-West), Maison de la Dermatologie, 8, rue Jules Ferry, 33290 Blanquefort, France; Dermatology department, Bordeaux university hospital, 33000 Bordeaux, France
| | - C Bergqvist
- CIC 1430 Inserm, Dermatology department, Henri-Mondor hospital, Assistance publique-Hôpitaux de Paris (AP-HP), 94000 Créteil, France
| | - S Ly
- Association des Dermato-Vénéréologues du Sud-Ouest (ADVSO, Association of Dermatologists and Venerologists of the French South-West), Maison de la Dermatologie, 8, rue Jules Ferry, 33290 Blanquefort, France; Dermatology department, Bordeaux university hospital, 33000 Bordeaux, France
| | - F Corgibet
- Fédération française de formation continue et d'évaluation en dermatologie et vénéréologie (FFFCEDV, French Federation of Continuing Education and Assessment in Dermatology), Maison de la Dermatologie, 10, cité Malesherbes, 75009 Paris, France
| | - J-F Seï
- Fédération française de formation continue et d'évaluation en dermatologie et vénéréologie (FFFCEDV, French Federation of Continuing Education and Assessment in Dermatology), Maison de la Dermatologie, 10, cité Malesherbes, 75009 Paris, France
| | - J Seneschal
- Dermatology department, Bordeaux university hospital, 33000 Bordeaux, France
| | - E Sbidian
- CIC 1430 Inserm, Dermatology department, Henri-Mondor hospital, Assistance publique-Hôpitaux de Paris (AP-HP), 94000 Créteil, France; EpiDermE, Paris-Est Créteil university, Val-de-Marne, 94000 Créteil, France
| | - M Beylot-Barry
- Dermatology department, Bordeaux university hospital, 33000 Bordeaux, France.
| |
Collapse
|
21
|
Chirpaz E, Warocquier J, Filisetti C, Beylot-Barry M, Bertolotti A, Sultan N. Epidemiology of cutaneous malignant melanoma in Reunion Island. Ann Dermatol Venereol 2022; 149:39-44. [DOI: 10.1016/j.annder.2021.05.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2021] [Revised: 03/13/2021] [Accepted: 05/06/2021] [Indexed: 10/19/2022]
|
22
|
Bassompierre A, Dalac S, Dreno B, Neidhardt EM, Maubec E, Capelle C, Andre F, Behal H, Dziwniel V, Bens G, Leccia MT, Meyer N, Granel-Brocard F, Beylot-Barry M, Dereure O, Basset-Seguin N, Mortier L. Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database. ESMO Open 2021; 6:100284. [PMID: 34689002 PMCID: PMC8551849 DOI: 10.1016/j.esmoop.2021.100284] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Revised: 09/12/2021] [Accepted: 09/22/2021] [Indexed: 11/01/2022] Open
Abstract
BACKGROUND Smoothened (SMO) inhibitors, blocking the sonic hedgehog pathway, have been approved for advanced basal cell carcinoma (aBCC). Safety analyses reveal a high rate of adverse events (AEs) and, most of the time, vismodegib is most commonly stopped when the best overall response is reached. The long-term evolution of aBCC after vismodegib discontinuation is poorly described. The aim of this study is to evaluate the efficacy and safety of the SMO inhibitors (SMOis) available (vismodegib and sonidegib) following rechallenge after complete response (CR) following an initial treatment by vismodegib. MATERIALS AND METHODS This real-life, retrospective, multicenter and descriptive study is based on an extraction from the CARADERM accredited database, including 40 French regional hospitals, of patients requiring BCC systemic treatment. RESULTS Of 303 patients treated with vismodegib, 110 achieved an initial CR. The vast majority of these patients (98.2%) stopped vismodegib, notably due to poorly tolerated AEs. The CARADERM database provided a median follow-up of 21 months (13.5-36.0 months) after CR. Of the 110 patients, 48.1% relapsed after a median relapse-free survival of 24 months (13.0-38.0 months). Among them, 35 patients were retreated by an SMOi and the overall response rate was 65.7% (34.3% of CR and 31.4% of partial response). The median duration of retreatment was 6.0 months (4.0-9.5 months). CONCLUSION Our real-life study, carried out on patients with complex clinical pictures, shows that after treatment discontinuation, 48.1% of patients achieved CR relapse within an average of 24 months (13.0-38.0 months). It emphasized that even though rechallenge can be considered as a therapeutic option, efficacy seems to decrease, suggesting the development of resistance mechanisms.
Collapse
Affiliation(s)
- A Bassompierre
- Department of Dermatology, Lille University, CHU Lille, Lille, France.
| | - S Dalac
- Department of Dermatology, Dijon University Hospital, Dijon, France
| | - B Dreno
- Department of Dermatology, Dieu Hospital, Nantes, France
| | - E M Neidhardt
- Department of Dermatology, Léon Bérard Center, Lyon, France
| | - E Maubec
- Department of Dermatology, AP-HP, Avicenne University Hospital, Bobigny, France
| | - C Capelle
- Department of Dermatology, Lille University, CHU Lille, Lille, France
| | - F Andre
- Department of Dermatology, Lille University, CHU Lille, Lille, France
| | - H Behal
- Health Technology and Medical Practice Assessment, ULR 2694-METRICS, Lille University Hospital, University of Lille, Lille, France
| | - V Dziwniel
- Department of Dermatology, Lille University, CHU Lille, Lille, France; Languages Department, Centrale Lille Institut, Villeneuve d'Ascq, France
| | - G Bens
- Department of Dermatology, Orleans Regional Hospital, Orleans, France
| | - M T Leccia
- Department of Dermatology, Grenoble University Hospital, Grenoble, France
| | - N Meyer
- Department of Dermatology, IUC and CHU de Toulouse, Toulouse, France
| | - F Granel-Brocard
- Department of Dermatology, Nancy University Hospital, Nancy, France
| | - M Beylot-Barry
- Department of Dermatology, Bordeaux University Hospital, Bordeaux, France
| | - O Dereure
- Department of Dermatology, University of Montpellier, Montpellier, France
| | - N Basset-Seguin
- Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris University Hospital, Paris, France
| | - L Mortier
- Department of Dermatology, Lille University, CHU Lille, Lille, France; INSERM U1189, CARADERM, CHU Lille, Lille, France
| |
Collapse
|
23
|
Monnet P, Herms F, Djermane M, Dalac S, Dereure O, Dréno B, Beylot-Barry M, Mortier L, Basset-Seguin N. Characterization of patients with advanced basal cell carcinoma progressing while receiving Hedgehog pathway inhibitors. Br J Dermatol 2021; 186:579-581. [PMID: 34817864 DOI: 10.1111/bjd.20808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2021] [Revised: 09/30/2021] [Accepted: 10/09/2021] [Indexed: 11/30/2022]
Affiliation(s)
- P Monnet
- Dermatology Department, AP-HP, Saint-Louis Hospital, Paris, France
| | - F Herms
- Dermatology Department, AP-HP, Saint-Louis Hospital, Paris, France.,CARADERM (Cancers RAres en DERMatologie), Lille, France
| | - M Djermane
- Dermatology Department, AP-HP, Saint-Louis Hospital, Paris, France.,CARADERM (Cancers RAres en DERMatologie), Lille, France
| | - S Dalac
- CARADERM (Cancers RAres en DERMatologie), Lille, France.,Dermatology Department, Dijon Bourgogne University Hospital, Dijon, France
| | - O Dereure
- CARADERM (Cancers RAres en DERMatologie), Lille, France.,Dermatology Department, Montpellier University Hospital, Montpellier, France
| | - B Dréno
- CARADERM (Cancers RAres en DERMatologie), Lille, France.,Dermatology Department, Nantes University Hospital, Nantes, France
| | - M Beylot-Barry
- CARADERM (Cancers RAres en DERMatologie), Lille, France.,Dermatology Department, Saint-André Hospital, Bordeaux, France
| | - L Mortier
- CARADERM (Cancers RAres en DERMatologie), Lille, France.,Dermatology Department, Lille University Hospital, Lille, France
| | - N Basset-Seguin
- Dermatology Department, AP-HP, Saint-Louis Hospital, Paris, France.,CARADERM (Cancers RAres en DERMatologie), Lille, France
| |
Collapse
|
24
|
Legrand A, Quintard B, Garrouteigt C, Beylot-Barry M, Broc G. From neglect to earlier diagnosis: a qualitative meta-synthesis of psycho-social factors associated with consultation delay in advanced basal cell carcinoma. PSYCHOL HEALTH MED 2021; 27:1793-1804. [PMID: 34251919 DOI: 10.1080/13548506.2021.1952281] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Local malignant potential of basal cell carcinoma (BCC) can lead at advanced stages to the destruction of underlying tissues and significant morbidity. The primary risk factor for progression of advanced basal cell carcinoma (aBCC) is the long duration of the tumour, which results from delay in seeking medical care. To assess the implication of psycho-social factors in the delay before the first medical consultation among patients with aBCC, in order to identify potentially targetable factors enabling earlier diagnosis. Three-step qualitative meta-synthesis: (1) systematic review of the literature; (2) structured qualitative analysis of these documents; (3) construction of a logical model. After screening, 81 articles were included. Self-neglect and denial in patients are roundly put forward as the main obstacles to consultation. We found that avoidance behaviour, mistaken interpretation and banalisation of symptoms, and fear of treatment all played a role. The strongest motivation to seek help comes from the realisation that new symptoms may be dangerous; the role of interpersonal surroundings is highlighted as helpful. Patient delay has multifactorial origins in aBCC, especially self-neglect ranging from denial of tumours to conscious refusal of treatment.
Collapse
Affiliation(s)
- A Legrand
- Department of Dermatology, Bordeaux University Hospital, Bordeaux University, Bordeaux, France
| | - B Quintard
- INSERM U1219, Bordeaux Population Health Research Centre, Team: Handicap, Activity, Cognition, Health, Bordeaux, France
| | - C Garrouteigt
- Department of Dermatology, Bordeaux University Hospital, Bordeaux University, Bordeaux, France
| | - M Beylot-Barry
- Department of Dermatology, Bordeaux University Hospital, Bordeaux University, Bordeaux, France.,INSERM U1053, UMR Bariton, Oncogenesis of Cutaneous Lymphoma, University of Bordeaux, Bordeaux, France
| | - G Broc
- Department of Psychology, Paul Valéry Montpellier 3, University of Montpellier, Montpellier, France
| |
Collapse
|
25
|
Bourlond F, Battistella M, Amici JM, Dousset L, Vergier B, Beylot-Barry M, Cribier B. Clinicopathologic analysis of trichoblastoma and comparison with nodular basal cell carcinoma. Ann Dermatol Venereol 2021; 148:177-182. [PMID: 34176642 DOI: 10.1016/j.annder.2021.03.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Revised: 12/15/2020] [Accepted: 03/18/2021] [Indexed: 10/21/2022]
Abstract
BACKGROUND Trichoblastoma (TB) is an uncommon benign follicular tumour for which clinical data is limited since most reports originate from pathology studies. OBJECTIVE To describe the clinical aspects of TB. METHODS This is an ancillary study of a prospective multicentre cohort of 2710 clinically suspected basal cell carcinoma (BCC), including 935 nodular BCCs. Sixty-two cases were TB: they were analysed and compared to 935 nodular BCCs. RESULTS TB mostly occurred in females (61% vs. 43% for BCC, P<0.01) of mean age 63 years. They were located on the head and neck, mainly on the nose and forehead, in 87% of cases. The mean size was 8.1mm, 77% were<10mm (55% of BCCs, P<0.001), 8% were ulcerated (vs. 21% of BCCs, P<0.02), and 47% persisted for more than 1 year (34% of BCCs, P<0.05). Most cases had a clinical presentation similar to nodular BCC, except for 5 small, flat, white papules and 1 anfractuous plaque. LIMITATIONS Cases originated from a series of tumours clinically suspected as BCCs. DISCUSSION Some 2.6% of tumours clinically diagnosed as BCC are in fact TB. TB occurs on the head, are more frequent in women, and are smaller and of longer duration than BCC. In most cases, clinical diagnosis on clinical grounds is difficult.
Collapse
Affiliation(s)
- F Bourlond
- Dermatology Clinic, Strasbourg University Hospitals, 1, place de l'Hôpital, 67091 Strasbourg, France.
| | - M Battistella
- Pathology Department, Saint-Louis Hospital AP-HP, Paris University, INSERM U976, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - J-M Amici
- Dermatology Department, Bordeaux University Hospital, Saint-André Hospital, 1, rue Jean-Burguet, 33000 Bordeaux, France
| | - L Dousset
- Dermatology Department, Bordeaux University Hospital, Saint-André Hospital, 1, rue Jean-Burguet, 33000 Bordeaux, France
| | - B Vergier
- Anatomic Pathology Department, Bordeaux University Hospital, Haut-Lévêque Hospital, avenue du Haut-Lévêque, 33604 Pessac, France
| | - M Beylot-Barry
- Dermatology Department, Bordeaux University Hospital, Saint-André Hospital, 1, rue Jean-Burguet, 33000 Bordeaux, France; Inserm U1053, 146, rue Léo-Saignat, 33000 Bordeaux, France
| | - B Cribier
- Dermatology Clinic, Strasbourg University Hospitals, 1, place de l'Hôpital, 67091 Strasbourg, France
| |
Collapse
|
26
|
Dugourd PM, Guillot P, Beylot-Barry M, Cogrel O. Surgical treatment of rhinophyma: Retrospective monocentric study and literature review. Ann Dermatol Venereol 2021; 148:172-176. [PMID: 34176641 DOI: 10.1016/j.annder.2021.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Revised: 01/14/2021] [Accepted: 02/05/2021] [Indexed: 11/19/2022]
Abstract
BACKGROUND Treatment of rhinophyma consists primarily of destructive procedures. There is currently no consensus regarding treatment. In this study, we propose an algorithm based on a cohort of 25 patients and a literature review. PATIENTS AND METHODS This was a retrospective study conducted between January 2016 and December 2018. The cosmetic outcome was evaluated by 2 independent assessors based on pre- and postoperative photographs. Patients were ranked according to the severity (mild, moderate, severe) of their rhinophyma. The different surgical methods used were cold blade excision or rhinoshave, electrosurgery or monopolar diathermy knife (MDK), and carbon dioxide laser (CO2 laser), either alone or in combination with another technique. All patients were contacted after the procedure to evaluate their satisfaction and to investigate for adverse effects. RESULTS Twenty-five patients were included retrospectively: 7 with mild rhinophyma (5 were treated by MDK, 1 by fractional CO2 laser, and 1 by cold-blade excision and TCA solution), 11 with moderate rhinophyma (2 were treated by MDK, 9 by continuous CO2 laser), and 7 with severe rhinophyma (2 were treated by MDK, 5 by MDK plus CO2 laser). Cosmetic outcomes were deemed good or excellent in 80% of cases, and 84% of patients were fully satisfied with the result. We observed 5 cases of hypertrophic scarring, 2 cases of hypopigmentation, 3 cases of notching of the nasal ala, and 7 cases of prolonged erythema, most of which were caused by the MDK technique. CONCLUSION A wide range of treatment options are available for rhinophyma. We suggest the use of cold-blade excision and trichloroacetic acid or fractional carbon dioxide laser for mild rhinophyma, continuous and pulsed CO2 laser for moderate rhinophyma, and MDK for severe rhinophyma.
Collapse
Affiliation(s)
- P-M Dugourd
- Dermatology Department, Dermatological Procedures Unit, Bordeaux University Hospital, Hôpital Saint-André, 1, rue Jean Burguet, 33000 Bordeaux, France
| | - P Guillot
- Dermatology Department, Dermatological Procedures Unit, Bordeaux University Hospital, Hôpital Saint-André, 1, rue Jean Burguet, 33000 Bordeaux, France
| | - M Beylot-Barry
- Dermatology Department, Dermatological Procedures Unit, Bordeaux University Hospital, Hôpital Saint-André, 1, rue Jean Burguet, 33000 Bordeaux, France
| | - O Cogrel
- Dermatology Department, Dermatological Procedures Unit, Bordeaux University Hospital, Hôpital Saint-André, 1, rue Jean Burguet, 33000 Bordeaux, France.
| |
Collapse
|
27
|
Beylot-Barry M, Seneschal J, Tran D, Bachelez H, Beneton N, Dupuy A, Joly P, Jullien D, Mahé E, Paul C, Richard MA, Sbidian E, Viguier M, Chosidow O, Tubach F. Characteristics of patients with psoriasis with Psoriasis Area and Severity Index < 10 treated with biological agents: results from the French PsoBioTeq cohort. Br J Dermatol 2021; 185:1052-1054. [PMID: 34128543 DOI: 10.1111/bjd.20585] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Revised: 06/13/2021] [Accepted: 06/13/2021] [Indexed: 01/20/2023]
Affiliation(s)
- M Beylot-Barry
- Dermatology Department, Bordeaux University Hospital, Bordeaux, France
| | - J Seneschal
- Dermatology Department, Bordeaux University Hospital, Bordeaux, France
| | - D Tran
- INSERM, Pierre Louis Institute for Epidemiology and Public Health, AP-HP, Paris, France.,Sorbonne University, Pitié Salpêtrière Hospitals, Public Health Department, Pharmacoepidemiology Centre, CIC-1422, Paris, France
| | - H Bachelez
- Dermatology Department, Saint-Louis Hospital, AP-HP, Université de Paris, Paris, France
| | - N Beneton
- Dermatology Department, Le Mans Hospital, Le Mans, France
| | - A Dupuy
- Dermatology Department, Rennes University Hospital, Rennes, France
| | - P Joly
- Dermatology Department, Rouen University Hospital, Rouen, France
| | - D Jullien
- Dermatology Department, Edouard Herriot Hospital, Lyon, France
| | - E Mahé
- Dermatology Department, Victor Dupouy Hospital, Argenteuil, France
| | - C Paul
- Dermatology Department, Toulouse University and University Hospital, Toulouse, France
| | - M-A Richard
- Dermatology Department, Marseille University Hospital, Marseille, France
| | - E Sbidian
- Dermatology Department, AP-HP, Henri Mondor University Hospitals, Paris-Est Créteil University, INSERM CIC1430, Créteil, France.,EpiDermE EA7379, Créteil, France
| | - M Viguier
- Dermatology-Venereology Department, Reims University Hospital, Reims, France
| | - O Chosidow
- Dermatology Department, AP-HP, Henri Mondor University Hospitals, Paris-Est Créteil University, INSERM CIC1430, Créteil, France.,Research Group Dynamic, EA7380, Créteil Health Faculty, Alfort National Veterinary School, USC ANSES, Paris-Est Créteil University, Créteil, France
| | - F Tubach
- INSERM, Pierre Louis Institute for Epidemiology and Public Health, AP-HP, Paris, France.,Sorbonne University, Pitié Salpêtrière Hospitals, Public Health Department, Pharmacoepidemiology Centre, CIC-1422, Paris, France
| |
Collapse
|
28
|
Skayem C, Beylot-Barry M, de Masson A, Dereure O, Ram-Wolff C, Bagot M, Vergier B, Battistella M, Ortonne N, Ingen-Housz-Oro S. Lymph node and visceral progression without erythroderma or blood worsening in erythrodermic cutaneous T-cell lymphoma: nine cases. Br J Dermatol 2021; 185:1061-1063. [PMID: 34128541 DOI: 10.1111/bjd.20580] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Revised: 06/08/2021] [Accepted: 06/13/2021] [Indexed: 12/01/2022]
Affiliation(s)
- C Skayem
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - M Beylot-Barry
- Department of Dermatology, Bordeaux University Hospital, Bordeaux, France.,INSERM U1053, Bordeaux Research in Translational Oncology (BaRITOn), Cutaneous Lymphoma Oncogenesis Team, Bordeaux University, Bordeaux, France.,French Cutaneous Lymphomas Study Group (GFELC), Paris, France
| | - A de Masson
- French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,Department of Dermatology, AP-HP, Saint-Louis Hospital, Université de Paris, INSERM U976, Paris, France
| | - O Dereure
- French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,Department of Dermatology, University of Montpellier and INSERM U1058 Pathogenesis and Control of Chronic Infections, Montpellier, France
| | - C Ram-Wolff
- French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,Department of Dermatology, AP-HP, Saint-Louis Hospital, Université de Paris, INSERM U976, Paris, France
| | - M Bagot
- French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,Department of Dermatology, AP-HP, Saint-Louis Hospital, Université de Paris, INSERM U976, Paris, France
| | - B Vergier
- INSERM U1053, Bordeaux Research in Translational Oncology (BaRITOn), Cutaneous Lymphoma Oncogenesis Team, Bordeaux University, Bordeaux, France.,French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,Department of Pathology, Bordeaux University Hospital, Bordeaux, France
| | - M Battistella
- French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,Department of Pathology, AP-HP, Saint-Louis Hospital, Université de Paris, INSERM U976, Paris, France
| | - N Ortonne
- French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,Department of Pathology, AP-HP, Henri Mondor Hospital, Créteil, France.,Paris Est Créteil University (UPEC) and IMRB, INSERM U955 Team Ortonne (NFL), Créteil, France
| | - S Ingen-Housz-Oro
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.,French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,University Paris Est Créteil EpiDermE, Créteil, France
| |
Collapse
|
29
|
costedoat I, Leroy-Colavolpe V, Dousset L, Beylot-Barry M, Doutre M. Cellulite de Wells à type d’œdème récidivant du visage : 3 cas. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.03.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
30
|
Bergqvist C, Beylot-Barry M, Ram-Wolff C, Vergier B, Bagot M, Battistella M, Dalle S, Balme B, Merlio JP, Durupt F, Le Corre Y, Bonnet N, Le Bozec P, Skowron F, Vivard-Wallee I, Dereure O, Brunet-Possenti F, Ingen-Housz-Oro S, Ortonne N. Lymphomatoid papulosis types D and E: a multicentre series of the French Cutaneous Lymphomas Study Group. Clin Exp Dermatol 2021; 46:1441-1451. [PMID: 33987864 DOI: 10.1111/ced.14730] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/10/2021] [Indexed: 11/30/2022]
Abstract
BACKGROUND Lymphomatoid papulosis (LyP) type D (LyP D) and type E (LyP E) have recently been described in small series of cases or isolated case reports. AIM To further describe the clinical and histological features of LyP D and E based on a retrospective multicentre study. METHODS The clinical and histopathological features of 29 patients with an initial diagnosis of LyP D or LyP E were retrospectively assessed using standardized forms. RESULTS After exclusion of 5 cases, 24 patients (14 LyP D, 10 LyP E) were enrolled in the study. The median follow-up was 2.5 years (range 1 month to 13 years). LyP D was characterized by multiple recurrent self-regressing small papules that developed central erosion or necrosis, whereas LyP E presented as papulonodular lesions that rapidly evolved into necrotic eschar-like lesions > 10 mm in size. Epidermal changes were more frequent in LyP D, whereas dermal infiltrates were deeper in LyP E. Anaplastic cytology was rare and the DUSP22 rearrangement was never observed. Two patients (8%) had an associated cutaneous lymphoma. CONCLUSION LyP D and E have distinct clinical findings and may be associated with other cutaneous lymphomas.
Collapse
Affiliation(s)
- C Bergqvist
- Department of, Dermatology, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - M Beylot-Barry
- Department of, Dermatology, Bordeaux University Hospital, Bordeaux, France.,Cutaneous Lymphoma Oncogenesis Team, INSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn), Bordeaux University, Bordeaux, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - C Ram-Wolff
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of, Dermatology, AP-HP, Hôpital Saint-Louis, Université de Paris, Paris, France
| | - B Vergier
- Department of, Pathology, Bordeaux University Hospital, Bordeaux, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - M Bagot
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of, Dermatology, AP-HP, Hôpital Saint-Louis, Université de Paris, Paris, France
| | - M Battistella
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of, Pathology, AP-HP, Hôpital Saint-Louis, Université de Paris, Paris, France
| | - S Dalle
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of, Dermatology, University Hospital of Lyon-Sud, Lyon, France
| | - B Balme
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of, Dermatology, University Hospital of Lyon-Sud, Lyon, France.,Department of, Pathology, University Hospital of Lyon-Sud, Lyon, France
| | - J P Merlio
- Cutaneous Lymphoma Oncogenesis Team, INSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn), Bordeaux University, Bordeaux, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - F Durupt
- Department of Dermatology, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France
| | - Y Le Corre
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of Dermatology, CHU Angers, Angers, France
| | - N Bonnet
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of Dermatology, Hôpitaux de Marseille, Marseille, France
| | - P Le Bozec
- Department of Dermatology, AP-HP, Hôpital Beaujon, Clichy, France
| | - F Skowron
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of Dermatology, Centre Hospitalier de Valence, Valence, France
| | | | - O Dereure
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of Dermatology, CHU de Montpellier, Montpellier, France
| | - F Brunet-Possenti
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of Dermatology, AP-HP, Hôpital Bichat, Paris, France
| | - S Ingen-Housz-Oro
- Department of, Dermatology, AP-HP, Hôpital Henri Mondor, Créteil, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - N Ortonne
- Department of, Pathology, AP-HP, Hôpital Henri Mondor, Créteil, France.,French Cutaneous Lymphomas Study Group, Paris, France.,Paris Est Creteil University (UPEC) and IMRB, INSERM U955 Team Ortonne (NFL), Créteil, France
| |
Collapse
|
31
|
Hacard F, Giraudeau B, d'Acremont G, Jegou MH, Jonville-Bera AP, Munck S, Pham BN, Mavoungou S, Cornillier H, Guillot B, Beylot-Barry M, Chosidow O, Maruani A. Guidelines for the management of chronic spontaneous urticaria: recommendations supported by the Centre of Evidence of the French Society of Dermatology. Br J Dermatol 2021; 185:658-660. [PMID: 33913519 PMCID: PMC8457139 DOI: 10.1111/bjd.20415] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Revised: 04/19/2021] [Accepted: 04/23/2021] [Indexed: 11/30/2022]
Affiliation(s)
- F Hacard
- Department of Allergology and Clinical Immunology, University Hospital of Lyon, 69495, Lyon, France
| | - B Giraudeau
- Universities of Tours and Nantes, 37000, Tours, France
| | | | - M-H Jegou
- Dermatology Office, 33290, Blanquefort, France
| | - A-P Jonville-Bera
- Universities of Tours and Nantes, 37000, Tours, France.,University Hospital of Tours, 37000, Tours, France
| | - S Munck
- Department of Teaching and Research in General Practice, University Nice Sophia Antipolis, 06000, Nice, France
| | - B-N Pham
- University Hospital of Reims, 51000, Reims, France
| | - S Mavoungou
- Centre of Evidence of the French Society of Dermatology, 75009, Paris, France
| | - H Cornillier
- University Hospital Centre of Tours, 37044, Tours CEDEX 9, France
| | - B Guillot
- University of Montpellier, 34000, Montpellier, France
| | - M Beylot-Barry
- University Hospital of Bordeaux, 33000, Bordeaux, France
| | - O Chosidow
- Centre of Evidence of the French Society of Dermatology, 75009, Paris, France.,AP-HP, Henri Mondor Hospital, Paris-Est University, 94010, Créteil, France
| | - A Maruani
- Universities of Tours and Nantes, 37000, Tours, France.,University Hospital Centre of Tours, 37044, Tours CEDEX 9, France
| |
Collapse
|
32
|
Guelimi R, Salle R, Dousset L, Assier H, Fourati S, Bhujoo Z, Barbarot S, Boulard C, Cazanave C, Colin A, Kostrzewa E, Lesort C, Levy Roy A, Lombart F, Marco Bonnet J, Marty L, Monfort JB, Riffaud L, Samimi M, Tardieu M, Sbidian E, Wolkenstein P, Le Cleach L, Beylot-Barry M. Non-acral skin manifestations during the COVID-19 epidemic: COVIDSKIN study by the French Society of Dermatology. J Eur Acad Dermatol Venereol 2021; 35:e539-e541. [PMID: 33914975 PMCID: PMC8242387 DOI: 10.1111/jdv.17322] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Revised: 03/26/2021] [Accepted: 04/16/2021] [Indexed: 01/08/2023]
Affiliation(s)
- R Guelimi
- Dermatology Department, Hôpital Henri Mondor, APHP, Créteil, France.,EA 7379 EpiDermE, UPEC, Créteil, France
| | - R Salle
- Dermatology Department, Hôpital Henri Mondor, APHP, Créteil, France.,EA 7379 EpiDermE, UPEC, Créteil, France
| | - L Dousset
- Dermatology Department, University Hospital Bordeaux, Bordeaux, France
| | - H Assier
- Dermatology Department, Hôpital Henri Mondor, APHP, Créteil, France.,EA 7379 EpiDermE, UPEC, Créteil, France
| | - S Fourati
- Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France
| | - Z Bhujoo
- Dermatology Department, Grand Hôpital de l'Est Francilien, Jossigny, France
| | - S Barbarot
- Dermatology Department, Nantes Université, University Hospital of Nantes, UMR 1280 PhAN, INRAE, Nantes, France
| | - C Boulard
- Department of Dermatology, Le Havre Hospital, Le Havre, France
| | - C Cazanave
- Infectious and Tropical Diseases Department, CHU Bordeaux, Bordeaux, France
| | - A Colin
- Dermatology Department, Hôpital Henri Mondor, APHP, Créteil, France.,EA 7379 EpiDermE, UPEC, Créteil, France
| | - E Kostrzewa
- Dermatology Department, Hôpital Robert Boulin, Libourne, France
| | - C Lesort
- Dermatology Department, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France
| | | | - F Lombart
- Dermatology, Amiens University Hospital Centre, Amiens, France
| | | | - L Marty
- Private Practice, Latresne, France
| | - J B Monfort
- AP-HP, Dermatology and Allergology Department, Hôpital Tenon, Sorbonne Université, Sorbonne University, Paris, France
| | | | - M Samimi
- Dermatology Department, University Hospital of Tours, INRA-University of Tours, ISP1282, Tours, France
| | - M Tardieu
- Dermatology Department, University Hospital of Grenoble Alpes, Grenoble, France
| | - E Sbidian
- Dermatology Department, Hôpital Henri Mondor, APHP, Créteil, France.,EA 7379 EpiDermE, UPEC, Créteil, France
| | - P Wolkenstein
- Dermatology Department, Hôpital Henri Mondor, APHP, Créteil, France.,EA 7379 EpiDermE, UPEC, Créteil, France
| | - L Le Cleach
- Dermatology Department, Hôpital Henri Mondor, APHP, Créteil, France.,EA 7379 EpiDermE, UPEC, Créteil, France
| | - M Beylot-Barry
- Dermatology Department, University Hospital Bordeaux, Bordeaux, France.,French Society of Dermatology, Paris, France
| |
Collapse
|
33
|
Hodak E, Sherman S, Papadavid E, Bagot M, Querfeld C, Quaglino P, Prince HM, Ortiz-Romero PL, Stadler R, Knobler R, Guenova E, Estrach T, Patsatsi A, Leshem YA, Prague-Naveh H, Berti E, Alberti-Violetti S, Cowan R, Jonak C, Nikolaou V, Mitteldorf C, Akilov O, Geskin L, Matin R, Beylot-Barry M, Vakeva L, Sanches JA, Servitje O, Weatherhead S, Wobser M, Yoo J, Bayne M, Bates A, Dunnill G, Marschalko M, Buschots AM, Wehkamp U, Evison F, Hong E, Amitay-Laish I, Stranzenbach R, Vermeer M, Willemze R, Kempf W, Cerroni L, Whittaker S, Kim YH, Scarisbrick JJ. Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study. Br J Dermatol 2021; 184:524-531. [PMID: 32574377 DOI: 10.1111/bjd.19303] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/30/2020] [Indexed: 12/12/2022]
Abstract
BACKGROUND Early-stage mycosis fungoides (MF) includes involvement of dermatopathic lymph nodes (LNs) or early lymphomatous LNs. There is a lack of unanimity among current guidelines regarding the indications for initial staging imaging in early-stage presentation of MF in the absence of enlarged palpable LNs. OBJECTIVES To investigate how often imaging is performed in patients with early-stage presentation of MF, to assess the yield of LN imaging, and to determine what disease characteristics promoted imaging. METHODS A review of clinicopathologically confirmed newly diagnosed patients with cutaneous patch/plaque (T1/T2) MF from PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) data. RESULTS PROCLIPI enrolled 375 patients with stage T1/T2 MF: 304 with classical MF and 71 with folliculotropic MF. Imaging was performed in 169 patients (45%): 83 with computed tomography, 18 with positron emission tomography-computed tomography and 68 with ultrasound. Only nine of these (5%) had palpable enlarged (≥ 15 mm) LNs, with an over-representation of plaques, irrespectively of the 10% body surface area cutoff that distinguishes T1 from T2. Folliculotropic MF was not more frequently imaged than classical MF. Radiologically enlarged LNs (≥ 15 mm) were detected in 30 patients (18%); only seven had clinical lymphadenopathy. On multivariate analysis, plaque presentation was the sole parameter significantly associated with radiologically enlarged LNs. Imaging of only clinically enlarged LNs upstaged 4% of patients (seven of 169) to at least IIA, whereas nonselective imaging upstaged another 14% (24 of 169). LN biopsy, performed in eight of 30 patients, identified N3 (extensive lymphomatous involvement) in two and N1 (dermatopathic changes) in six. CONCLUSIONS Physical examination was a poor determinant of LN enlargement or involvement. Presence of plaques was associated with a significant increase in identification of enlarged or involved LNs in patients with early-stage presentation of MF, which may be important when deciding who to image. Imaging increases the detection rate of stage IIA MF, and identifies rare cases of extensive lymphomatous nodes, upstaging them to advanced-stage IVA2.
Collapse
Affiliation(s)
- E Hodak
- Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva; affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - S Sherman
- Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva; affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - E Papadavid
- Athens University Medical School, Athens, Greece
| | - M Bagot
- Hospital St Louis, Paris, France
| | - C Querfeld
- City of Hope National Medical Center and Beckman Research Institute, Duarte, CA, USA
| | - P Quaglino
- Dermatologic Clinic, University of Turin Medical School, Turin, Italy
| | - H M Prince
- Sir Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia
| | - P L Ortiz-Romero
- Department of Dermatology, Hospital 12 de Octubre, Medical School, University Complutense, Madrid, Spain
| | - R Stadler
- Johannes Wesling University Medical Centre, Minden, Germany
| | - R Knobler
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - E Guenova
- University Hospital Zurich, Zurich, Switzerland
| | - T Estrach
- Hospital Clinico, University of Barcelona, Barcelona, Spain
| | - A Patsatsi
- Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece
| | - Y A Leshem
- Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva; affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - H Prague-Naveh
- Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva; affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - E Berti
- University of Milan, Milan, Italy
| | | | - R Cowan
- Christie Hospital, Manchester, UK
| | - C Jonak
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - V Nikolaou
- Athens University Medical School, Athens, Greece
| | - C Mitteldorf
- HELIOS Klinikum Hildesheim GmbH, University Medical Centre Göttingen, Göttingen, Germany
| | - O Akilov
- University of Pittsburgh School of Medicine, Pennsylvania, PA, USA
| | - L Geskin
- University of Columbia, New York, NY, USA
| | - R Matin
- Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | | | - L Vakeva
- Helsinki University Central Hospital, Helsinki, Finland
| | - J A Sanches
- University of São Paulo Medical School, São Paulo, SP, Brazil
| | - O Servitje
- Hospital Universatari de Bellvitge, Barcelona, Spain
| | | | - M Wobser
- University Hospital Wuerzburg, Wuerzburg, Germany
| | - J Yoo
- University Hospital Birmingham, Birmingham, UK
| | | | - A Bates
- University Hospital Southampton, Southampton, UK
| | - G Dunnill
- University Hospital Bristol, Bristol, UK
| | | | | | - U Wehkamp
- University Hospital Kiel, Kiel, Germany
| | - F Evison
- University Hospital Birmingham, Birmingham, UK
| | - E Hong
- Stanford University Medical Center, Stanford, CA, USA
| | - I Amitay-Laish
- Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva; affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - R Stranzenbach
- Johannes Wesling University Medical Centre, Minden, Germany
| | - M Vermeer
- Leiden University Medical Centre, Leiden, the Netherlands
| | - R Willemze
- Leiden University Medical Centre, Leiden, the Netherlands
| | - W Kempf
- Kempf and PFlatz, Histologische Diagnostik, Zurich, Switzerland
| | - L Cerroni
- Department of Dermatology, Research Unit Dermatopathology, Medical University of Graz, Graz, Austria
| | | | - Y H Kim
- Stanford University Medical Center, Stanford, CA, USA
| | | |
Collapse
|
34
|
Beytout Q, Pepiot J, Maruani A, Devulder D, Aubert R, Beylot-Barry M, Amici JM, Jullien D, Mahé E. Impact of the COVID-19 pandemic on children with psoriasis. Ann Dermatol Venereol 2021; 148:106-111. [PMID: 33637347 PMCID: PMC7901834 DOI: 10.1016/j.annder.2021.01.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 12/04/2020] [Accepted: 01/18/2021] [Indexed: 12/19/2022]
Abstract
Background Children with psoriasis may have been directly impacted by the COVID-19 pandemic and their illness may also have affected their ability to follow preventive measures. Objective To investigate the impact of the COVID-19 pandemic on children with psoriasis. Methods A survey of children (< 18 years) with psoriasis, conducted from June 10 to June 29, 2020. Results In total, 92 children were included: 71.7% had psoriasis lesions at the time of home lockdown while 45.2% were receiving systemic treatments, and two contracted COVID-19. During lockdown, psoriasis worsened in 47.3% of the children and 18.8% stopped their systemic treatments, mainly for reasons linked to the pandemic. A total of 41.3% had a consultation for psoriasis during lockdown (71.1% by teleconsultation): 39.5% due to worsening of their psoriasis and 21.1% for pandemic-related issues. Among patients not having a consultation during lockdown, 27.5% had a cancellation by the doctor and 9.3% had concerns over going to see the doctor. Finally, 22.8% of patients reported finding it difficult to respect hygiene measures because of their psoriasis, e.g., application of alcohol-based hand sanitizers (47.6%), handwashing routines (42.9%), and wearing a mask (28.6%). Conclusions This study demonstrates the major clinical impact of the COVID-19 pandemic on children with psoriasis. Teleconsultations played a key role in patient management as regards patient monitoring, provision of information, and renewal of treatments. It is vital that we learn from these data to improve and adapt the monitoring of chronic dermatoses in both children and adults in the event of a future health crisis.
Collapse
Affiliation(s)
- Q Beytout
- Service de dermatologie, hôpital Victor-Dupouy, 69, rue du Lieutenant Colonel-Prudhon, 95107 Argenteuil cedex, France
| | - J Pepiot
- Association France Psoriasis, 53, rue Compans, 75019 Paris, France
| | - A Maruani
- Inserm 1246-SPHERE, unité de dermatologie pédiatrique, service de dermatologie, CHRU Tours, université de Tours, 2, boulevard Tonnellé, 37000 Tours, France
| | - D Devulder
- Association France Psoriasis, 53, rue Compans, 75019 Paris, France
| | - R Aubert
- Association France Psoriasis, 53, rue Compans, 75019 Paris, France
| | - M Beylot-Barry
- Inserm u 1053. UMR BaRiton, service de dermatologie, hôpital Saint-André, CHU de Bordeaux, université de Bordeaux, 1, rue Jean-Burguet, 33000 Bordeaux, France
| | - J-M Amici
- Dermatologie, Cabinet Libéral, 36, avenue René-Cassagne, 33150 Cenon, France
| | - D Jullien
- Service de dermatologie, hôpital Edouard-Herriot, hôpitaux civils de Lyon, 5, place d'Arsonval, 69003 Lyon, France
| | - E Mahé
- Service de dermatologie, hôpital Victor-Dupouy, 69, rue du Lieutenant Colonel-Prudhon, 95107 Argenteuil cedex, France.
| |
Collapse
|
35
|
Bertolotti A, Sbidian E, Join-Lambert O, Bourgault-Villada I, Moyal-Barracco M, Perrot P, Jouan N, Yordanov Y, Sidorkiewicz S, Chazelas K, Bru-Daprés MF, Caumes E, Sei JF, Chosidow O, Beylot-Barry M. Guidelines for the management of hidradenitis suppurativa: recommendations supported by the Centre of Evidence of the French Society of Dermatology. Br J Dermatol 2020; 184:963-965. [PMID: 33278829 PMCID: PMC8247998 DOI: 10.1111/bjd.19710] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2020] [Revised: 12/02/2020] [Accepted: 12/02/2020] [Indexed: 11/28/2022]
Affiliation(s)
- A Bertolotti
- INSERM CIC1410, CHU Réunion, Saint Pierre, La Réunion, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Maubec E, Boubaya M, Petrow P, Beylot-Barry M, Basset-Seguin N, Deschamps L, Grob J, Dréno B, Scheer-Senyarich I, Bloch-Queyrat C, Leccia MT, Stefan A, Saiag P, Grange F, Meyer N, de Quatrebarbes J, Dinulescu M, Legoupil D, Machet L, Dereure O, Zehou O, Montaudié H, Wierzbicka-Hainaut E, Le Corre Y, Mansard S, Guegan S, Arnault JP, Dalac S, Aubin F, Alloux C, Lopez I, Cherbal S, Tibi A, Dalac S, Levy V. Étude de phase II de l’administration de pembrolizumab (MK-3475) en monothérapie et en première ligne chez des patients présentant un carcinome épidermoïde cutané non opérable. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
37
|
Le Cleach L, Dousset L, Assier H, Fourati S, Barbarot S, Boulard C, Bourseau Quetier C, Cambon L, Cazanave C, Colin A, Kostrzewa E, Lesort C, Levy Roy A, Lombart F, Marco-Bonnet J, Monfort J, Samimi M, Tardieu M, Wolkenstein P, Sbidian E, Beylot-Barry M. La majorité des engelures observées durant l’épidémie de COVID-19 ne semblent pas dues à l’infection par le SRAS-Cov-2. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
38
|
Ducharme O, Pouchot J, Amico S, Milpied B, Seneschal J, Beylot-Barry M, Pham-Ledard A. Omalizumab : une nouvelle option thérapeutique pour la pemphigoïde bulleuse. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
39
|
Menguy S, Mansour Y, Augereau O, Ortonne N, Balme B, Battistella M, Lamant L, Beltzung F, Szablewski V, Gaulard P, Bagot M, Beylot-Barry M, Vergier B. Impact des algorithmes du Groupe Français d’Étude des Lymphomes Cutanés sur le diagnostic anatomopathologique des lymphoproliférations cutanées. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
40
|
Toulemonde E, Marabelle A, Fléchon A, Chevret S, Simon C, Beylot-Barry M, Mortier L. AcSé Nivolumab : résultats préliminaires pour le carcinome trichoblastique. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
41
|
Pacaud A, Dousset L, Dorizy-Duong V, Gérard E, Beylot-Barry M, Pham-Ledard A. Infiltration granulomateuse alopéciante du cuir chevelu sous mogamulizumab : 2 cas. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
42
|
Beytout Q, Pepiot J, Maruani A, Devulder D, Aubert R, Beylot-Barry M, Amici JM, Jullien D, Mahé E. Impact de l’épidémie de Covid-19 sur le psoriasis de l’enfant en France. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
43
|
Valentin J, Gérard E, Dousset L, Prey S, Dutriaux C, Beylot-Barry M, Pham-Ledard A. Tolérance du cémiplimab en vie réelle : étude rétrospective monocentrique. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
44
|
Villani A, Amatore F, Tauber M, Guillot B, Viguier M, Beylot-Barry M, Jullien D. Impact des recommandations françaises sur les habitudes de prescription des traitements systémiques pour le psoriasis modéré à sévère. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
45
|
Khammari A, Dinulescu M, Nguyen JM, Cassecuel J, Maillard H, Le Duff F, Machet L, Beylot-Barry M, Legoupil D, Wierzbicka-Hainaut E, Bedane C, Leccia MT, Debarbieux S, Meyer N, Monestier S, Bens G, Denis M, Vourch M, Bossard C, Vergier B, Dréno B. L’efficacité de l’imiquimod dans la prise en charge du mélanome de Dubreuilh in situ (lentigo malin). Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
46
|
Guicheney M, Pham-Ledard A, Beylot-Barry M, Dousset L, Prey S, Dutriaux C, Gerard E, Dequidt L. Encorafénib-binimétinib : des résultats encourageants notamment en intracrânien. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
47
|
Dobos G, de Masson A, Ram-Wolff C, Beylot-Barry M, Pham-Ledard A, Ortonne N, Oro S, Battistella M, d’Incan M, Rouanet J, Franck F, Vignon-Pennamen MD, Franck N, Carlotti A, Boulinguez S, Lamant L, Petrella T, Dalac S, Joly P, Courville P, Rivet J, Dereur O, Amatore F, Taix S, Grange F, Durlach A, Quéreux G, Josselin N, Moulonguet I, Mortier L, Dubois R, Maubec E, Laroche L, Michel L, Templier I, Barete S, Nardin C, Augereau O, Vergier B, Bagot M. Changements dans l’épidémiologie des lymphomes cutanés primitifs en France : une analyse de 8593 patients du registre du Groupe Français d’Etude des Lymphomes Cutanés (GFELC). Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
48
|
Condamina M, Tran VT, Penso L, Hotz C, Guillem P, Villani A, Perrot P, Bru MF, Jacquet E, Nassif A, Bachelez H, Wolkenstein P, Beylot-Barry M, Richard MA, Ravaud P, Viguier M, Sbidian E. Caractéristiques cliniques des patients atteints d’hidradénite suppurée participants à la e-cohorte ComPaRe et comparaison avec les données de la littérature. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
49
|
Merhi R, Ducharme O, Pham-Ledard A, Beylot-Barry M, Gérard E. Évolution fatale d’un syndrome de lyse tumorale sous double immunothérapie (anti-CTLA-4 et anti-PD1). Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
50
|
Dorizy-Vuong V, Chambon R, Berrouet L, Pinton F, Layan A, Gauthier-Lucas E, Doutre MS, Joseph JP, Beylot-Barry M, Taïeb A. SmartDerm : mise en place de la télé-expertise dermatologique dans trois départements en déprise médicale de Nouvelle-Aquitaine. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|